Ed Miseta

Ed Miseta

For more than a decade, Ed Miseta served as the Chief Editor of Clinical Leader. His tenure sadly ended in July 2023 when he passed away after a two-year battle with multiple myeloma. During his time as Chief Editor, Ed interviewed hundreds of executives from sponsor companies, patients, and technology and service providers. He regularly reported on best practices and advancements in clinical trials, detailing how both small and large sponsor companies navigate the changing landscape. In addition to his writing, Ed hosted numerous Clinical Leader Live! digital events that allowed his audience to listen to and interact with experts throughout clinical trials on a host of important issues. Beyond his duties for Clinical Leader, Ed frequently moderated and spoke at many conferences and events related to clinical trials.

Ed studied Business Economics at Penn State University and earned a Master’s degree in Business Administration. He spent 10 years in banking and investments and taught economics at Penn State for 8 years before joining Clinical Leader.


  • How BMS Uses AI To Improve Study Design And Reduce Costs

    In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. The partnership will allow BMS to use machine learning to enhance clinical trial design and execution.

  • Clinical Sites Are Optimistic, Despite Growing Challenges

    The last few years have not been easy for sites involved with conducting clinical research. The onset of the pandemic in 2020 created numerous challenges, including the implementation of new technologies and operating models, the leveraging of remote staff, and virtual facilities. Despite the ongoing challenges, global sites remain optimistic about the future of clinical trials.

  • DTRA Looks At The Future Of Decentralized Trials

    In November 2022, the Decentralized Trials & Research Alliance (DTRA) held its annual meeting in Boston. The meeting was a chance for members of the Alliance to come together to discuss the progress that has been made and what the future holds for the emerging technology.

  • How One Pharma Company Is Embracing Digital Technologies

    The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

  • The Future Of TransCelerate: Clinical Trial Modernization

    In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.

  • Overcome Recruitment Challenges Of Black And Rural Patients

    Patient recruitment for clinical trials is difficult and can cause many studies to be delayed or cancelled. Two groups that are particularly difficult to recruit are patients of color and those living in remote and rural areas of the country. In those two instances, overcoming recruitment barriers can prove to be particularly difficult.

  • How To Educate Regulators On What Matters To Patients

    With the greater emphasis on patient-centricity, patients are valued as an active participant in their own care. There is an increased emphasis on evaluating treatment benefit using patient-centric concepts and input from the patient community. Regulators now urge sponsors and researchers to systematically engage patients and caregivers to define the disease burden and unmet needs.

  • Boehringer Ingelheim Implements One Medicine Technology Platform

    For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

  • AstraZeneca Hopes To Advance Oncology RWE

    AstraZeneca is an emerging leader in the chronic lymphocytic leukemia space. It now hopes to develop treatments so patients can avoid chemotherapy, with the hope those therapies will prolong survival in patients while also producing a better quality of life.

  • How Are DCTs Impacting Your Clinical Sites?

    Where do your sites stand on DCTs? For this article, we spoke with three site experts who discussed the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more.